The top targets, EGFR, CASP3, SRC, TNF, MMP9, STAT3, and ERBB2, were selected as the core targets for molecular docking with the core compound of HQHG for ITP treatment. The gene discussed is MMP9; the disease is autoimmune thrombocytopenic purpura.